| |
In this eBook discover more about the future of orphan drugs and the ways companies are enabling their drugs to get to market faster. Download today!
|
|
|
Wednesday, February 15, 2023 | 1pm ET / 10am PT Biosimilars continue to gain global acceptance and momentum, with 2023 set to be a landmark year. However, the complex and ever-changing regulatory environment is still a challenge. Join industry experts for an important discussion on biosimilar regulatory trends and key insights for navigating the biosimilar regulatory landscape. Register now.
|
|
| By Nick Paul Taylor Teva Pharmaceutical has opened another front in its expansion into long-acting injectables, kicking off a phase 3 clinical trial of a prospect based on the same technology as its near-approval schizophrenia drug. |
|
|
|
By Nick Paul Taylor The FDA is making argenx wait on an approval decision for subcutaneous efgartigimod. After receiving more information from argenx, the regulator extended the review and pushed the PDUFA date back to the summer. |
By Nick Paul Taylor Aptar Pharma wants to reduce the waste generated by your nasal spray pumps. With the launch of APF Futurity, the drug delivery specialist has made a metal-free, multi-dose nasal spray pump available to meet demand for recyclable products. |
By Nick Paul Taylor Sensorion has partnered to improve the delivery of its hearing loss gene therapy OTOF-GT. Working with Eveon, the French biotech is aiming to develop an injection system for getting its therapies to the inner ear. |
|
Watch this OnDemand webinar to hear experts discuss a cross-functional approach to ensure appropriate containment systems for high potency products from development to commercialization. Download today!
|
|
By Eric Sagonowsky,Kevin Dunleavy,Fraiser Kansteiner,Angus Liu,Zoey Becker Heading into 2022, top drugmakers had $1.7 trillion in dealmaking firepower, fueling expectations among analysts that the industry was due for a gangbusters M&A year. Well, that didn’t quite pan out. |
By James Waldron,Annalee Armstrong,Nick Paul Taylor After a slow 2022, will we see a return to form for biopharma M&A? And, if so, which biotechs does Big Pharma have in its sight? Here are our predictions. |
Fierce podcastsDon't miss an episode |
| This week on "The Top Line," we hear from Stacie Dusetzina, Ph.D., a professor at Vanderbilt University's Department of Health Policy, about what the IRA means for the pharma industry. We'll also discuss what we can expect from the biotech industry in 2023. |
|
|---|
|
|
|
Tuesday, Feb 28, 2023 | 11:00am ET The heavy lifting for the pharmaceutical industry to comply with the November 2023 DSCSA go-live date is still ongoing. One item now finalized is to ensure that the required data exchange through the supply chain is only done with trusted, authorized, and registered trading partners. Join us for this discussion to stay up-to-date on this important legislation and be prepared for compliance. Register now.
|
|
| WhitepaperAccelerating bioproduction towards high performance and scale Sponsored by: Capgemini Americas Inc. |
| eBook Catalent’s Carla Vozone discusses the significant trends in the Orally Inhaled & Nasal Drug Delivery (OINDP) segment including large molecules and novel indications. Sponsored By: Catalent |
| Whitepaper Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored By: Catalent |
| |
|
